Details for Patent: 11,752,190
✉ Email this page to a colleague
Which drugs does patent 11,752,190 protect, and when does it expire?
Patent 11,752,190 protects ZILBRYSQ and is included in one NDA.
This patent has sixty patent family members in twenty-six countries.
Summary for Patent: 11,752,190
| Title: | Modulators of complement activity |
| Abstract: | The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. |
| Inventor(s): | Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco |
| Assignee: | UCB Holdings Inc |
| Application Number: | US17/065,560 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; Dosage form; |
Drugs Protected by US Patent 11,752,190
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-001 | Oct 17, 2023 | RX | Yes | Yes | 11,752,190 | ⤷ Start Trial | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Start Trial | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | 11,752,190 | ⤷ Start Trial | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Start Trial | |||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-003 | Oct 17, 2023 | RX | Yes | Yes | 11,752,190 | ⤷ Start Trial | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,752,190
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 107027 | ⤷ Start Trial | |||
| Argentina | 121381 | ⤷ Start Trial | |||
| Argentina | 134913 | ⤷ Start Trial | |||
| Australia | 2016370210 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
